Segments (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Reportable Segment Loss

The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:


		Three Months Ended March 31,
		2026				2025
Chronic cough in IPF clinical trial expense		$	1,688			$	2,882
Refractory chronic cough clinical trial expense			1,078				818
Other clinical trials and studies 1			1,553				48
Clinical trial material			1,299				234
Other clinical development expenses 2			1,523				1,418
Employee compensation (excluding stock compensation expense)			3,159				2,958
Stock-based compensation expense			2,191				1,208
Other segment items 3			2,397				1,899
Interest income, net			(1,696	)			(1,125	)
Net loss		$	13,192			$	10,340

(1) Includes expense related to the Company’s Phase 1 NDA supportive studies

(2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance.

(3) Includes general administrative expense, other (expense) income, net and income tax benefit.